Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...
copdnewstoday37 分钟
FDA approves Dupixent for adults with poorly controlled COPD
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
Too Old to Operate1 小时
PSI Outperforms CURB-65 and qSOFA in Predicting Mortality and Costs for Patients with COPD ...
The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...
FiercePharma3 天
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
The American Journal of Managed Care3 天
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
The American Journal of Managed Care3 天
COPD Poses Public Health Risk for US Smokers, Nonsmokers
While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among ...
emjreviews.com10 分钟
Sanofi and Regeneron’s allergy drug approved as first biologic for COPD
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...
Yicai Global6 小时
China Approves World's First Targeted COPD Drug
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...
Medpage Today on MSN3 天
First-Ever Biologic Approved for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...